Navigation

Hybrid Treatment of a subtrochanteric femoral fracture

Indications: Femur

Patient with idiopathic renal Franconi Syndrome presented to the ER after a low-energetic fall. Conventional imaging revealed a right subtrochanteric femoral fracture, severely decreased bone quality and cannulated collum femoris screws on the contralateral side. Regular plate-screw osteosynthesis or cephalomedullary implantation was deemed insufficient, due to a high iatrogenic and periprosthetic fracture probability. The decision was made to perform a plate screw osteosynthesis combined with an intramedullary polymer bone enhancement (IlluminOss), to minimize this risk. No complications occurred perioperatively. The patient was able to walk independently two months postoperatively.


Anterior-posterior view: right-sided subtrochanteric femoral fracture, left-sided collum femoris screws

Medio-lateral view: subtrochanteric femoral fracture.

Post-operative anterior–posterior view: DHS osteosynthesis with intramedullary bone enhancement.

 

 

US Indication: The IlluminOss Photodynamic Bone Stabilization System is indicated for use in skeletally mature patients in the treatment of traumatic, fragility, pathological, and impending pathological fractures of the humerus, radius, ulna, clavicle, pelvis, fibula, metacarpals, metatarsals, and phalanges. The IlluminOss Photodynamic Bone Stabilization System can also be used in conjunction with FDA-cleared fracture fixation systems to provide supplemental fixation in these anatomic sites. The IlluminOss System may be used in the femur and tibia to provide supplemental fixation to an anatomically appropriate FDA-cleared fracture fixation system.

 

EU Indication: The Photodynamic Bone Stabilization System is indicated for use in fracture alignment reduction. It provides stabilization for bone fractures using a minimally invasive technique in which the bone is not subjected to significant weight bearing forces. This IlluminOss procedure pack is intended for use in treatment of the metacarpal, phalange, clavicle, radius, ulna, distal radius, olecranon and fibula. It is also intended for use in treatment of acute fractures of the humerus, and impending and actual pathological fractures of the humerus from metastatic bone disease.

 

For more detailed procedural information including Warnings, Cautions, Risks & Contraindications, please see the respective IlluminOss Surgical Technique Guide, Package insert, or visit www.illuminoss.com.

Version: 900636-C

Other Posts